中化新网讯 12月21—22日，第四届现代农业发展论坛在湖北宜昌召开。中国石油和化学工业联合会(简 称中国石化联)党委书记、会长李云鹏出席。论坛以"生物创新、生物制造、绿色发展"为主题，聚焦生 物技术前沿趋势，深入探讨"十五五"期间如何以生物科技创新赋能农业强国建设。 "生物制造将在'十五五'迎来黄金发展时期。"第十四届全国政协委员、国家新材料专咨委主任、工信部 电子科技委主任、工信部原副部长王江平在视频讲话中指出，生物制造是引领未来的战略必争之地，已 经成为全球产业竞争的焦点，对于破解资源环境约束、重塑产业竞争力、培育新质生产力具有十分重要 的意义。"我们要聚焦短板领域，不断夯实生物制造高质量发展的根基，推动生物制造与现代农业深度 融合，提升农产品质量，助力绿色循环，筑牢国家粮食安全根基。"他说。 中国工程院院士、贵州大学校长宋宝安强调，"十五五"作为我国农业迈向现代化的关键阶段，唯有牢牢 锚定科技强国目标，紧抓新一轮科技革命和产业变革机遇，才能在农业强国建设的征程上迈出坚实步 伐。农业新质生产力的核心是科技创新驱动下的全要素升级，既体现在生物创新、智能装备等技术革新 的核心引擎作用上，也落脚于产业链融合、 ...

12月18日，2025生物制造大会在重庆举办。会上发布的数据显示，目前，我国生物制造产业总规模达到 1.1万亿元，生物发酵产品产量占全球70%以上。 国家注册审核员、广东更佳昊国际认证有限公司总经理李锦堤对《证券日报》记者表示，万亿元规模展 现出我国生物制造产业的强大实力与深厚积累。作为战略性新兴产业，生物制造的发展壮大不仅能催生 新的经济增长点，还能带动医药、化工、燃料等领域协同创新，为提升国家竞争力、应对全球挑战提供 了强劲动能。 多方共筑产业生态 生物制造是以工业生物技术为核心，利用基因工程、合成生物学等技术，通过微生物、酶或细胞等生物 体进行物质加工与转化的制造模式，其应用范围涵盖生物医药、新材料、新能源、生态环保及现代农业 等多个领域，具有低碳循环、绿色清洁特征。 医疗健康方面，武汉禾元生物科技股份有限公司基于水稻胚乳细胞生物反应器的表达体系开发了多款医 药产品。今年7月份，公司旗下I类创新药产品奥福民 重组人白蛋白注射液（水稻）成功入选2024年生 物制造标志性产品名单（第一批）名单。 生物材料方面，上海凯赛生物技术股份有限公司深耕新型生物基材料领域，其开发的生物基聚酰胺连续 纤维增强复合材料强度 ...

每经头条（nbdtoutiao）——秒光、售罄！银行大额存单成稀缺资源，2%以上产品很难抢，有的门槛高 达1000万元！专家：存款利率或长期下行 每经AI快讯，远大控股（SZ 000626，收盘价：8.03元）12月5日晚间发布公告称，公司第十一届2025年 度第九次董事会会议于2025年12月5日以电子通信方式召开。会议审议了《关于收购控股子公司福建凯 立生物制品有限公司约14.88%股权的议案》等文件。 2025年1至6月份，远大控股的营业收入构成为：商品贸易占比99.36%，生物农业占比0.35%，特油加工 占比0.26%，物流代理服务占比0.02%。 截至发稿，远大控股市值为41亿元。 （记者 王晓波） ...

Core Viewpoint - Jiangxi Miyutai Suisheng Biotechnology Co., Ltd. has been established with a registered capital of 3.33 million RMB, focusing on various agricultural and biotechnology activities [1] Company Overview - The legal representative of the company is Huang Fei [1] - The registered capital is 3.33 million RMB [1] Business Scope - The company is involved in licensed projects such as aquaculture, edible mushroom seed production, and related import/export activities [1] - It also engages in general projects including agricultural scientific research, edible mushroom cultivation, and the development of biological feed and materials [1] - Other activities include the research and development of biological pesticides, organic fertilizers, and biomass fuel sales [1] - The company is permitted to conduct operations in accordance with relevant approvals and licenses [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002496 证券简称：*ST辉丰 公告编号：2025-043 江苏辉丰生物农业股份有限公司 关于公司诉讼事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 江苏辉丰生物农业股份有限公司（以下简称"辉丰股份"或"公司"）近日收到江苏省盐城市中级人民法院 送达的民事裁决书（编号：（2024）苏09民初61号），现公告如下： 辉丰股份与北京航天关于承揽合同的纠纷。 诉讼事项的具体情况详见公司于2024年11月7日在指定披露媒体披露的《关于公司诉讼事项的公告》 （公告编号：2024-035）。 二、裁定的主要内容 辉丰股份因需要完善证据，向法院提出暂时撤回诉讼申请，盐城中院裁定：准许江苏辉丰生物农业股份 有限公司撤诉。案件受理费141800 元，减半收取70900元，由江苏辉丰生物农业股份有限公司负担。 三、其它尚未披露的诉讼仲裁事项 截止目前，公司没有其它应披露而未披露的重大诉讼、仲裁事项，一般诉讼 事项详见公司定期报告中 的相关章节。 一、诉讼事项的基本情况 1、诉讼当事人 原告：江苏辉丰生 ...

Core Viewpoint - The Guangzhou Baiyun District has launched a three-year action plan (2026-2028) to accelerate the high-quality development of the biomanufacturing industry, aiming to achieve an output value exceeding 50 billion yuan by 2028 and establish a nationally competitive biomanufacturing industry pilot zone [1][2]. Group 1: Industry Development Plan - The action plan outlines the construction of a "11221" industrial ecosystem, which includes the establishment of one biomanufacturing innovation center, one pilot base, two achievement transformation platforms, two phases of over 1,000 acres of biomanufacturing industrial parks, and a biomanufacturing fund cluster with a scale of 10 billion yuan [2][3]. - The biomanufacturing sector is recognized as a core area for cultivating new productive forces and is a strategic competitive point for the nation [1][2]. Group 2: Current Industry Landscape - Baiyun District is a significant hub for the cosmetics industry, with over 1,200 licensed cosmetics manufacturing enterprises, accounting for about 20% of the national total, and an industry scale projected to reach 36.14 billion yuan by 2024 [2]. - The biopharmaceutical industry in the region has surpassed 31.1 billion yuan, featuring leading companies such as Guangzhou Pharmaceutical Group and Hutchison Whampoa, fostering a collaborative development advantage through "leading enterprises + research empowerment + stock upgrading" [2]. Group 3: Industrial Park and Investment - The Guangzhou Baiyun Biomanufacturing Industrial Park, as a core component of the "11221" system, is crucial for spatial layout and cluster development, with the first phase covering approximately 450 acres focused on biomedicine, cell genes, and beauty products, while the second phase will cover about 900 acres across five major industry groups [3]. - A biomanufacturing industry fund cluster with a total scale of 10 billion yuan has been established, with the first phase raising 1 billion yuan, targeting investments across the entire lifecycle of biomanufacturing enterprises from startup to Pre-IPO [3].

Core Insights - The article highlights the development of a billion-level "Northern Bio Valley" in Dezhou, focusing on the growth of the biotechnology industry through collaboration and innovation [1][2][4] Industry Overview - Dezhou is concentrating on five key areas within the biotechnology sector: biomanufacturing, biomedicine, bio-agriculture, biomedical engineering, and biomass energy, aiming for high-end, clustered, and international development [2][3] - The city has established a clear framework for its biotechnology industry, with 153 enterprises in the sector and projected revenue of 40.4 billion yuan in 2024 [2] Innovation and Collaboration - Innovation is identified as the core driver for overcoming challenges and seizing development opportunities, supported by numerous national and provincial innovation platforms [3] - Dezhou has established long-term collaborations with over 40 universities and research institutions, holding nearly 300 patents related to biopreparation [3] Regional Development - Different regions within Dezhou are focusing on specific areas of biotechnology, such as biomanufacturing in Yucheng and medical devices in Qihe, creating a diverse and collaborative development landscape [4] - The city has mechanisms in place for regular roadshows and result transformation, targeting investors, entrepreneurs, and industry experts to facilitate efficient connections among technology, capital, market, and policy [4] Future Outlook - Dezhou aims to target cutting-edge fields such as synthetic biology, gene cell therapy, and AI pharmaceuticals, with plans to establish high-level innovation platforms and pilot bases [4] - The city is committed to enhancing its industrial cluster development, optimizing its industrial layout, and attracting leading enterprises and major projects to achieve the goal of becoming a billion-level "Northern Bio Valley" [4]

Group 1 - The 2025 Biomanufacturing Industry Conference was held in Guangzhou, focusing on the development of the biomanufacturing industry and gathering various stakeholders including government officials, industry experts, and investors [1][2] - The biomanufacturing industry is identified as a strategic emerging industry in China's 14th Five-Year Plan, with a target of reaching a total output value of approximately 500 billion yuan by 2027 and aiming for a trillion yuan scale by 2035 [2][3] - Guangzhou has established a dedicated working group for biomanufacturing development, aiming to create a competitive biomanufacturing industry cluster by 2027, focusing on five key areas: biomedicine, biomaterials, biological food, biomedicine, and biological agriculture [2][3] Group 2 - Huangpu District and Guangzhou Development Zone are positioned as the core areas for biomanufacturing, with a comprehensive policy support system established to facilitate the entire chain from R&D to industrialization [3][4] - The Guangzhou Frontier Biotechnology and Biomanufacturing Innovation Promotion Center was officially inaugurated, aiming to create a collaborative innovation platform involving government, industry, academia, and research institutions [4][5] - The conference featured various sessions on topics such as "Pharmaceutical Health and Beauty," "Agriculture, Food, and Materials Industry," and "Artificial Intelligence and Biomanufacturing Innovation," highlighting the innovative achievements of local enterprises [5][6] Group 3 - Local companies like Chuang'er Biotechnology and Muen Biotechnology showcased their innovative products, with Chuang'er receiving regulatory approval for its collagen product and Muen being recognized for its extensive microbial library [5][6] - Guangzhou aims to position biomanufacturing as a strategic pillar for high-quality urban development, attracting global biotech companies and top talent to foster innovation and create a globally influential biomanufacturing innovation hub [6]

Core Insights - The article discusses the rapid development and investment in the biomanufacturing sector in China, highlighting various projects and initiatives aimed at establishing mid-test platforms across multiple regions [5][6][12]. Investment and Project Developments - In Chongqing, a total of 32 projects with an investment of 14.53 billion yuan were signed, focusing on biomanufacturing, biomedicine, and other high-tech industries [5]. - The Chongqing Biomanufacturing Industry Pilot Platform aims to create a national-level mid-test platform for biomanufacturing, emphasizing intelligent biological fermentation and related technologies [6]. - The platform is part of a broader initiative that includes 1,252 key projects with a total investment of approximately 3.2 trillion yuan planned for 2025 [6]. Regional Initiatives - Changde Economic Development Zone is also advancing its synthetic biomanufacturing mid-test conversion platform, with significant construction progress reported [7][8]. - The Changde platform has a total investment of 169 million yuan and will feature multiple mid-test production lines to cater to various scales and types of biomanufacturing [8]. National Support and Policy Framework - Multiple provinces, including Guangdong, Shanghai, and Sichuan, are actively supporting the establishment of mid-test platforms, with specific funding and policy frameworks in place [10][11][12]. - The Ministry of Industry and Information Technology and the National Development and Reform Commission have set a goal to cultivate over 20 mid-test capability construction platforms by 2027, aiming to serve more than 200 enterprises [12].

Core Insights - China's bio-economy is showing a positive trend, with significant advancements in CAR-T cell therapy, original drug production, and brain-machine interface medical devices, positioning the country as the second-largest biopharmaceutical market globally [1][2] Industry Overview - The global bio-manufacturing industry is receiving heightened attention from major economies, with increased funding for genetic and cell engineering research, biomass utilization, and bio-based product development [2] - The number of CAR-T clinical research centers worldwide has grown to 2069 in 2024, a 60% increase from 1297 in 2020, with China hosting 388 centers, ranking second globally [2] - China has achieved a record high in the proportion of self-developed new drugs, with 93 new drugs approved by the National Medical Products Administration in 2024, marking a five-year peak [2] Research and Development - In 2024, China published over 20,000 SCI papers in the medical equipment field, leading globally in research output [3] - The bio-economy in China is characterized by a robust industrial foundation, with significant growth in the pharmaceutical and chemical sectors driven by advancements in synthetic biology and high-throughput screening technologies [3] Industry Transformation - The bio-industry is transitioning from "quantitative accumulation" to "qualitative leap," focusing on core technology breakthroughs, product quality upgrades, and enhancing supply chain resilience [4] - Notable innovations include the approval of the world's first "rice-derived" human serum albumin injection and the launch of the world's first 5.0T whole-body MRI system [4] Future Prospects - Innovations in synthetic biology and gene editing are driving rapid growth in bio-manufacturing, outpacing GDP growth, and positioning the bio-economy as a crucial sector in the future global economy [5]